Economic impact of adopting pemetrexed plus cisplatin for malignant pleural mesothelioma into Scottish clinical practice

被引：0
|
作者：
Chetty, M
Cordony, A
Davey, P
Karampela, K
Le Reun, C
Watt, M
机构：
[1] MTAG Pty Ltd, Chatswood, NSW, Australia
[2] Eli Lilly & Co, Basingstoke, Hants, England
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67239-7
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A33 / A33
页数：1
相关论文
共 50 条
  • [21] Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
    Ceresoli, GL
    Zucali, PA
    Favaretto, AG
    Grossi, F
    Bidoli, P
    Del Conte, G
    Ceribelli, A
    Bearz, A
    Morenghi, E
    Cavina, R
    Marangolo, M
    Parra, HJS
    Santoro, A
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) : 1443 - 1448
  • [22] Pemetrexed for diffuse malignant pleural mesothelioma
    Manegold, C
    Aisner, J
    SEMINARS IN ONCOLOGY, 2002, 29 (02) : 30 - 35
  • [23] Pemetrexed therapy for malignant pleural mesothelioma
    Puto, K
    Garey, JS
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (04) : 678 - 683
  • [24] IMPACT OF DIHYDROFOLATE REDUCTASE EXPRESSION FOR CLINICAL BENEFIT FROM PEMETREXED IN MALIGNANT PLEURAL MESOTHELIOMA
    Christoph, Daniel C.
    Wohlschlaeger, Jeremias
    Neumann, Volker
    Gauler, Thomas C.
    Poettgen, Christoph
    Peglow, Anja
    Tannapfel, Andrea
    Schuler, Martin
    Hirsch, Fred R.
    Eberhardt, Wilfried
    Theegarten, Dirk
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1052 - S1053
  • [25] Pemetrexed plus cisplatin (DON in patients with malignant peritoneal mesothelioma (AbM).
    Karthaus, M
    Metzner, D
    Maher, G
    Plahl, A
    Wert, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 666S - 666S
  • [26] ONCOS-102 and pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma
    Ponce Aix, S.
    Viteri, S.
    Bosch-Borrera, J.
    Kuryk, L.
    Hakonen, T.
    Vetrhus, S.
    Jaderberg, M.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Combination Chemotherapy with Cisplatin, Pemetrexed, and Nivolumab for Malignant Pleural Mesothelioma: A Trial in Progress
    Fujimoto, N.
    Aoe, K.
    Kozuki, T.
    Oze, I.
    Kato, K.
    Kishimoto, T.
    Hotta, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S746 - S746
  • [28] Radiation Recall Dermatitis after Pemetrexed Cisplatin chemotherapy in malignant pleural mesothelioma
    Berdel, C.
    Ruebe, C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 : 7 - 7
  • [29] Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma
    Skopljanac, Ivan
    Segrt, Ivana
    Mise, Kornelija
    Vukovac, Emilija Lozo
    Biocina, Anita Tolic
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [30] Interaction and cross resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines
    Kitazono, Miyako
    Takiguch, Yuichi
    Kitazono, Satoru
    Ashinuma, Hironori
    Kitamura, Atsushi
    Tada, Yuji
    Kurosu, Katsushi
    Sakaida, Emiko
    Sekine, Ikuo
    Tanabe, Nobuhiro
    Tagawa, Masatoshi
    Tatsumi, Koichiro
    CANCER RESEARCH, 2012, 72
12345